Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps.
暂无分享,去创建一个
George Loizou | Harvey J Clewell | Hugh A Barton | Walter Schmitt | Martin Spendiff | Bette Meek | Ursula Gundert-Remy | Frédéric Y Bois | Harrie Buist | Gerhard Goerlitz | H. Buist | W. Schmitt | H. Clewell | F. Bois | G. Loizou | J. Bessems | B. Meek | U. Gundert-Remy | H. Barton | M. d’Yvoire | Jos Bessems | Michel Bouvier d'Yvoire | M. Spendiff | G. Goerlitz
[1] Alessandro Giuliani,et al. The Integrated Use of Alternative Approaches for Predicting Toxic Hazard , 1995 .
[2] Harvey J. Clewell,et al. Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry , 2002, Critical reviews in toxicology.
[3] Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. , 1994, Toxicology in vitro : an international journal published in association with BIBRA.
[4] L Finkelstein,et al. Validation of simple and complex models in physiology and medicine. , 1984, The American journal of physiology.
[5] Hugh A Barton,et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.
[6] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.
[7] Kwang-Hyun Cho,et al. Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-κ B Signal Transduction Pathway , 2003, Simul..
[8] George Loizou,et al. Physiologically based pharmacokinetic modelling , 2003 .
[9] H J Clewell,et al. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. , 1999, Risk analysis : an official publication of the Society for Risk Analysis.
[10] George Loizou,et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[11] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .
[12] L A Cox,et al. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. , 1996, Environmental health perspectives.
[13] H. Barton,et al. Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. , 1996, Toxicology.
[14] G. Wells. Propylene oxide. , 2018, IARC monographs on the evaluation of carcinogenic risks to humans.
[15] N Oreskes,et al. Evaluation (not validation) of quantitative models. , 1998, Environmental health perspectives.
[16] Hasso Seibert,et al. In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. , 2003, Toxicology.
[17] Carolyn Vickers,et al. IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .
[18] A. Saltelli,et al. Sensitivity analysis of an environmental model: an application of different analysis methods , 1997 .
[19] Ursula Gundert-Remy,et al. The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective. , 2002, The Science of the total environment.
[20] Hugh A Barton,et al. Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[21] Johannes J M van de Sandt,et al. Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. , 2006, Toxicology letters.
[22] H J Clewell,et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.
[23] E Dybing,et al. [Drinking water and health]. , 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[24] M. Cario-André,et al. In Vitro Approaches , 2010 .
[25] G. L. Kedderis. Extrapolation of in vitro enzyme induction data to humans in vivo. , 1997, Chemico-biological interactions.
[26] G. Tucker,et al. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. , 2003, British journal of clinical pharmacology.
[27] Aldo Rescigno,et al. The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[28] G. Csanády,et al. Kinetics of propylene oxide metabolism in microsomes and cytosol of different organs from mouse, rat, and humans. , 2001, Toxicology and applied pharmacology.
[29] J W Fisher,et al. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.
[30] Weihsueh A. Chiu,et al. Pharmacokinetic/Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments , 2006 .
[31] Harvey J Clewell,et al. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.
[32] K. Czene,et al. Dosimetry by means of DNA and hemoglobin adducts in propylene oxide-exposed rats. , 2003, Toxicology and applied pharmacology.
[33] Malcolm Rowland,et al. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.
[34] Malcolm Rowland,et al. Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[35] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of pharmacokinetics and biopharmaceutics.
[36] H J Clewell,et al. Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.
[37] D. Segerbäck,et al. Propylene oxide in blood and soluble nonprotein thiols in nasal mucosa and other tissues of male Fischer 344/N rats exposed to propylene oxide vapors--relevance of glutathione depletion for propylene oxide-induced rat nasal tumors. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[38] S J Franks,et al. A mathematical model for the absorption and metabolism of formaldehyde vapour by humans. , 2005, Toxicology and applied pharmacology.
[39] J B Houston,et al. The Integrated Use of Alternative Methods in Toxicological Risk Evaluation , 1999, Alternatives to laboratory animals : ATLA.
[40] H J Clewell,et al. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.
[41] Klaus Schilling,et al. Practical Application of , 2006 .
[42] A. Rostami-Hodjegan,et al. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.
[43] Michael A. Gallo,et al. Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .
[44] J. Miners,et al. Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism , 1994 .
[45] A. J. MacDonald,et al. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. , 2000, Regulatory toxicology and pharmacology : RTP.
[46] J B Houston,et al. An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project. , 1999, Toxicology in vitro : an international journal published in association with BIBRA.
[47] G. Csanády,et al. A physiological toxicokinetic model for inhaled propylene oxide in rat and human with special emphasis on the nose. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[48] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[49] Cindy Sonich-Mullin,et al. Practical application of kinetic data in risk assessment--an IPCS initiative. , 2003, Toxicology letters.
[50] K. Krishnan,et al. Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. , 2005, Chemical research in toxicology.
[51] Harvey J Clewell,et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[52] Jennifer Seed,et al. A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.
[53] M. Babich. Risk assessment of low-level chemical exposures from consumer products under the U.S. Consumer Product Safety Commission chronic hazard guidelines. , 1998, Environmental health perspectives.
[54] Jennifer Seed,et al. Overview: Using Mode of Action and Life Stage Information to Evaluate the Human Relevance of Animal Toxicity Data , 2005, Critical reviews in toxicology.
[55] R A Becker,et al. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. , 2007, Regulatory toxicology and pharmacology : RTP.
[56] Gunnar Johanson,et al. The Use of Biokinetics and in Vitro Methods in Toxicological Risk Evaluation , 1996 .
[57] J. N. Blancato,et al. Update to the health assessment document and addendum for dichloromethane (methylene chloride): pharmacokinetics, mechanism of action, and epidemiology. External review draft , 1987 .
[58] J. Caldwell,et al. Key Scientific Issues in the Health Risk Assessment of Trichloroethylene , 2006, Environmental health perspectives.
[59] M Dourson,et al. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. , 2002, Toxicology.